Viralgen Partners with Elaaj Bio to Advance Gene Therapy for CDKL5 Deficiency Disorder
Viralgen partners with Elaaj Bio to advance an AAV-based gene therapy program for CDKL5 Deficiency Disorder, leveraging specialised manufacturing expertise.
AAV Vector Manufacturing | 06/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy